We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-10 of 1,135

Novartis Pharmaceuticals Corp. v. Breckenridge Pharmaceutical
  • Knobbe Martens
  • USA
  • December 10 2018

A patent filed before the June 8, 1995 effective date of the Uruguay Round Agreements Act (URAA) has a 17 year term that begins on its issuance date

Obviousness-Type Double Patenting Just Became Less of a Problem for Innovators
  • Pepper Hamilton LLP
  • USA
  • December 10 2018

The Federal Circuit recently issued a pair of decisions concerning the Gilead doctrine, which allowed later-issuing patents to be obviousness-type

Normal Double Patenting Rules Don’t Apply When the Patents Straddle the URAA
  • Harness, Dickey & Pierce, PLC
  • USA
  • December 7 2018

In Novaritis Pharmaceuticals Corporation v. Breckenridge Pharmaceutical Inc., 2017-2173, 2017-2175, 2017-2176, 2017-2178, 2017-2179, 2017-2180

CJEU rules on whether the NHS reimbursing off-label medicinal products for cost-cutting purposes conflicts with Directive 200183EC
  • Herbert Smith Freehills LLP
  • European Union, Italy
  • November 23 2018

Novartis Farma S.p.A. v Italian Medicines Agency and Roche Italia S.p.A. On 21 November 2018, the CJEU issued an important decision in Novartis Farma

Dealing with costs in trusts and probate proceedings - Part 1: liability for trustees
  • Kingsley Napley
  • United Kingdom
  • September 26 2018

The recent decision in John David Sheffield V (1) John Julian Lionel George Sheffield, Lionel Julian Sheffield & Simon Robert Alexander Sheffield (As

Surprising or not:Nnoerr-Pennington Doctrine protects Novartis from two class action antitrust lawsuits
  • Faruki Ireland Cox Rhinehart & Dusing PLL
  • USA
  • September 24 2018

A defendant accused of violating the antitrust laws has a powerful, well-established defense, if it can prove it, of immunity based on the

CAR-T gets the green light in Europe
  • Bristows
  • United Kingdom, European Union
  • September 20 2018

On Monday 27 August, the first two CAR-T therapies were authorised for use in the European Union, following EMA approval: Novartis’ Kymriah and Kite

PTAB Upholds GILENYA Method of Treatment Patent, Prompting New ANDA Litigation
  • Jones Day
  • USA
  • July 30 2018

In Apotex Inc. v. Novartis AG, IPR2017-00854, Paper 109 (Jul. 11, 2018), the PTAB held that the claims of U.S. Patent No. 9,187,405 were not

La vicenda AvastinLucentis prossima all’epilogo. Un’infrazione antitrust che potrebbe trovarsi senza oggetto
  • De Berti Jacchia Franchini Forlani Studio Legale
  • European Union, Italy
  • July 25 2018

Nel prossimo autunno, il Consiglio di Stato sarà chiamato a decidere la controversia tra F. Hoffmann-La Roche Ltd (Roche), Roche SpA (Roche Italia)

Motions for Additional Discovery at the PTAB
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • June 25 2018

The Patent Trial and Appeal Board (“PTAB”) rarely grants motions for additional discovery filed by a party in an inter partes review (“IPR”)